File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: Cytogenetic and molecular features

TitleTherapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: Cytogenetic and molecular features
Authors
Issue Date2001
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/humpath
Citation
Human Pathology, 2001, v. 32 n. 1, p. 126-129 How to Cite?
AbstractThe use of all trans-retinoic acid and combination chemotherapy has made acute promyelocytic leukemia (APL) a potentially curable leukemia. Late sequelae of the treatment of APL have therefore become an important consideration in the overall treatment strategy. We report a patient with APL who achieved complete clinical and molecular remission after treatment with the topoisomerase II inhibitors daunorubicin, mitoxantrone, etoposide, and the anti-metabolite cytosine arabinoside. Seven years later, she developed therapy-related myelodysplastic syndrome (t-MDS) without any evidence of relapse of the APL clone. Karyotypic and molecular cytogenetic analysis showed complex cytogenetic aberrations, including deletion of the long arm of chromosome 5, monosomy 7, but without rearrangement of the MLL gene/11q23. Interestingly, this case would be classified clinically as "epipodophyllotoxin related MDS," but pathologically as "alkylating-agent related MDS" according to the recently proposed World Health Organization (WHO) classification system for MDS. This case of t-MDS in an APL patient in durable remission highlights the importance of avoiding long-term treatment related toxicities, as APL is a potentially curable leukemia. Copyright © 2001 by W.B. Saunders Company.
Persistent Identifierhttp://hdl.handle.net/10722/76449
ISSN
2015 Impact Factor: 2.791
2015 SCImago Journal Rankings: 1.363
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_HK
dc.contributor.authorLam, CCKen_HK
dc.contributor.authorMa, ESKen_HK
dc.contributor.authorMan, Cen_HK
dc.contributor.authorWan, Ten_HK
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2010-09-06T07:21:21Z-
dc.date.available2010-09-06T07:21:21Z-
dc.date.issued2001en_HK
dc.identifier.citationHuman Pathology, 2001, v. 32 n. 1, p. 126-129en_HK
dc.identifier.issn0046-8177en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76449-
dc.description.abstractThe use of all trans-retinoic acid and combination chemotherapy has made acute promyelocytic leukemia (APL) a potentially curable leukemia. Late sequelae of the treatment of APL have therefore become an important consideration in the overall treatment strategy. We report a patient with APL who achieved complete clinical and molecular remission after treatment with the topoisomerase II inhibitors daunorubicin, mitoxantrone, etoposide, and the anti-metabolite cytosine arabinoside. Seven years later, she developed therapy-related myelodysplastic syndrome (t-MDS) without any evidence of relapse of the APL clone. Karyotypic and molecular cytogenetic analysis showed complex cytogenetic aberrations, including deletion of the long arm of chromosome 5, monosomy 7, but without rearrangement of the MLL gene/11q23. Interestingly, this case would be classified clinically as "epipodophyllotoxin related MDS," but pathologically as "alkylating-agent related MDS" according to the recently proposed World Health Organization (WHO) classification system for MDS. This case of t-MDS in an APL patient in durable remission highlights the importance of avoiding long-term treatment related toxicities, as APL is a potentially curable leukemia. Copyright © 2001 by W.B. Saunders Company.en_HK
dc.languageengen_HK
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/humpathen_HK
dc.relation.ispartofHuman Pathologyen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - adverse effects - therapeutic useen_HK
dc.subject.meshChromosome Aberrationsen_HK
dc.subject.meshChromosome Deletionen_HK
dc.subject.meshChromosomes, Human, Pair 5 - geneticsen_HK
dc.subject.meshChromosomes, Human, Pair 7 - geneticsen_HK
dc.subject.meshCytogenetic Analysisen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshIn Situ Hybridization, Fluorescenceen_HK
dc.subject.meshKaryotypingen_HK
dc.subject.meshLeukemia, Promyelocytic, Acute - complications - drug therapyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMonosomyen_HK
dc.subject.meshMyelodysplastic Syndromes - etiology - genetics - pathologyen_HK
dc.subject.meshNucleic Acid Hybridization - methodsen_HK
dc.titleTherapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: Cytogenetic and molecular featuresen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0046-8177&volume=32&issue=1&spage=126&epage=129&date=2000&atitle=Therapy-related+myelodysplastic+syndrome+after+eradication+of+acute+promyelocytic+leukemia:+Cytogenetic+and+molecular+featuresen_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1053/hupa.2001.21128en_HK
dc.identifier.pmid11172306-
dc.identifier.scopuseid_2-s2.0-0035126096en_HK
dc.identifier.hkuros63687en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035126096&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume32en_HK
dc.identifier.issue1en_HK
dc.identifier.spage126en_HK
dc.identifier.epage129en_HK
dc.identifier.isiWOS:000166729700020-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridLam, CCK=16947291300en_HK
dc.identifier.scopusauthoridMa, ESK=7202039934en_HK
dc.identifier.scopusauthoridMan, C=7005722377en_HK
dc.identifier.scopusauthoridWan, T=25623981600en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats